{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:58:02Z","timestamp":1790686682258,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T00:00:00Z","timestamp":1787356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40262-026-01688-4","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T09:17:13Z","timestamp":1787390233000},"page":"1527-1540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, Elimination and Dialyzability of HRS-9231 in Patients with Varying Degrees of Renal Impairment"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct06657560","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9213-5417","authenticated-orcid":false,"given":"Qiwen","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luhai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulimire","family":"Muhetaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengrui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,22]]},"reference":[{"issue":"6","key":"1688_CR1","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1039\/b510982p","volume":"35","author":"P Caravan","year":"2006","unstructured":"Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev. 2006;35(6):512\u201323.","journal-title":"Chem Soc Rev"},{"issue":"1","key":"1688_CR2","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jmri.29367","volume":"61","author":"E Kanal","year":"2025","unstructured":"Kanal E, Maki JH, Schramm P, et al. Evolving characteristics of gadolinium-based contrast agents for MR imaging: a systematic review of the importance of relaxivity. J Magn Reson Imaging. 2025;61(1):52\u201369.","journal-title":"J Magn Reson Imaging"},{"key":"1688_CR3","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/RLI.0000000000000684","volume":"55","author":"E Lancelot","year":"2020","unstructured":"Lancelot E, Raynaud J-S, Desch\u00e9 P. Current and future MR contrast agents: seeking a better chemical stability and relaxivity for optimal safety and efficacy. Invest Radiol. 2020;55:578\u201388.","journal-title":"Invest Radiol"},{"issue":"2","key":"1688_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1148\/radiol.2018181151","volume":"289","author":"RJ McDonald","year":"2018","unstructured":"McDonald RJ, Levine D, Weinreb J, et al. Gadolinium retention: a research roadmap from the 2018 NIH\/ACR\/RSNA workshop on gadolinium chelates. Radiology. 2018;289(2):517\u201334.","journal-title":"Radiology"},{"issue":"8","key":"1688_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081816","volume":"12","author":"S Gallo-Bernal","year":"2022","unstructured":"Gallo-Bernal S, Patino-Jaramillo N, Calixto CA, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease after the use of gadolinium-based contrast agents: a review for the cardiovascular imager. Diagnostics (Basel). 2022;12(8):1816.","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"1688_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1053\/j.ajkd.2020.07.012","volume":"77","author":"MR Rudnick","year":"2021","unstructured":"Rudnick MR, Wahba IM, Leonberg-Yoo AK, et al. Risks and options with gadolinium-based contrast agents in patients with CKD: a review. Am J Kidney Dis. 2021;77(4):517\u201328.","journal-title":"Am J Kidney Dis"},{"key":"1688_CR7","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00330-017-5065-8","volume":"28","author":"IA Dekkers","year":"2018","unstructured":"Dekkers IA, Roos R, Van Der Molen AJ. Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol. 2018;28:1579\u201384.","journal-title":"Eur Radiol"},{"key":"1688_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1148\/radiol.12112783","volume":"265","author":"L Yang","year":"2012","unstructured":"Yang L, et al. Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Radiology. 2012;265:248\u201353.","journal-title":"Radiology"},{"key":"1688_CR9","unstructured":"ACR\u00ae Manual on Contrast Media. ACR Committee on Drugs and Contrast Media. 2025. https:\/\/www.acr.org\/clinical-resources\/clinical-tools-and-reference\/contrast-manual."},{"key":"1688_CR10","unstructured":"ESUR Guidelines on Contrast Agents. European Society of Urogenital Radiology. VERSION 10.0. https:\/\/www.esur.org\/wp-content\/uploads\/2022\/03\/ESUR-Guidelines-10_0-Final-Version.pdf."},{"issue":"7","key":"1688_CR11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/RLI.0000000000000252","volume":"51","author":"N Murata","year":"2016","unstructured":"Murata N, Gonzalez-Cuyar LF, Murata K, et al. Macrocyclic and other non-group 1 gadolinium contrast agents deposit low levels of gadolinium in brain and bone tissue: preliminary results from 9 patients with normal renal function. Invest Radiol. 2016;51(7):447\u201353.","journal-title":"Invest Radiol"},{"issue":"3","key":"1688_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1148\/radiol.15150025","volume":"275","author":"RJ McDonald","year":"2015","unstructured":"McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial gadolinium deposition after contrast-enhanced MR imaging. Radiology. 2015;275(3):772\u201382.","journal-title":"Radiology"},{"issue":"10","key":"1688_CR13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/RLI.0000000000000072","volume":"49","author":"Y Errante","year":"2014","unstructured":"Errante Y, Cirimele V, Mallio CA, et al. Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol. 2014;49(10):685\u201390.","journal-title":"Invest Radiol"},{"issue":"3","key":"1688_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1148\/radiol.2015150805","volume":"275","author":"E Kanal","year":"2015","unstructured":"Kanal E, Tweedle MF. Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology. 2015;275(3):630\u20134.","journal-title":"Radiology"},{"issue":"9","key":"1688_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"key":"1688_CR16","unstructured":"Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5(5):303\u2013313."},{"issue":"6","key":"1688_CR17","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jaad.2010.08.041","volume":"65","author":"M Girardi","year":"2011","unstructured":"Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol. 2011;65(6):1095-1106.e7.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1688_CR18","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/RLI.0000000000000764","volume":"56","author":"A Bradu","year":"2021","unstructured":"Bradu A, Penescu M, Pitrou C, et al. Pharmacokinetics, dialysability, and safety of gadopiclenol, a new gadolinium-based contrast agent, in patients with impaired renal function. Invest Radiol. 2021;56(8):486\u201393.","journal-title":"Invest Radiol"},{"key":"1688_CR19","unstructured":"Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER). Pharmacokinetics in Patients with Impaired Renal Function \u2014 Study Design, Data Analysis, and Impact on Dosing and Labeling (Guidance for Industry). 2024."},{"issue":"Suppl 1","key":"1688_CR20","first-page":"S12","volume":"27","author":"SJ McLachlan","year":"1992","unstructured":"McLachlan SJ, Eaton S, De Simone DN. Pharmacokinetic behavior of gadoteridol injection. Invest Radiol. 1992;27(Suppl 1):S12\u20135.","journal-title":"Invest Radiol"},{"issue":"7","key":"1688_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1097\/00004424-199407000-00008","volume":"29","author":"T Staks","year":"1994","unstructured":"Staks T, Schuhmann-Giampieri G, Frenzel T, et al. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol. 1994;29(7):709\u201315.","journal-title":"Invest Radiol"},{"issue":"7","key":"1688_CR22","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/00004424-199907000-00001","volume":"34","author":"SK Swan","year":"1999","unstructured":"Swan SK, Lambrecht LJ, Townsend R, et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol. 1999;34(7):443\u20138.","journal-title":"Invest Radiol"},{"issue":"7","key":"1688_CR23","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/RLI.0000000000000556","volume":"54","author":"J Hao","year":"2019","unstructured":"Hao J, Bourrinet P, Desch\u00e9 P. Assessment of pharmacokinetic, pharmacodynamic profile, and tolerance of gadopiclenol, a new high relaxivity GBCA, in healthy subjects and patients with brain lesions (phase I\/IIa study). Invest Radiol. 2019;54(7):396\u2013402.","journal-title":"Invest Radiol"},{"key":"1688_CR24","unstructured":"ELUCIREMTM (gadopiclenol) injection, for intravenous use. Initial U.S. Approval: 2022. FULL PRESCRIBING INFORMATION. Revised: 3\/2025."},{"key":"1688_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106749","volume":"196","author":"X He","year":"2024","unstructured":"He X, Matsuki S, Li K, et al. Pharmacokinetics, safety, and tolerability of the novel tetrameric gadolinium-based MRI contrast agent gadoquatrane in healthy Chinese and Japanese men: two randomized dose-escalation studies including concentration-QTc modeling. Eur J Pharm Sci. 2024;196:106749.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"1688_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/00004424-200001000-00004","volume":"35","author":"B Tombach","year":"2000","unstructured":"Tombach B, Bremer C, Reimer P, et al. Pharmacokinetics of 1M gadobutrol in patients with chronic renal failure. Invest Radiol. 2000;35(1):35\u201340.","journal-title":"Invest Radiol"},{"key":"1688_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/BF00175436","volume":"2","author":"A Chachuat","year":"1992","unstructured":"Chachuat A, Molinier P, Bonnemain B, et al. Pharmacokinetics and tolerance of Gd-DOTA (DOTAREM) in healthy volunteers and in patients with chronic renal failure. Eur Radiol. 1992;2:326\u20139.","journal-title":"Eur Radiol"},{"issue":"7","key":"1688_CR28","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S1076-6332(98)80191-8","volume":"5","author":"P Joffe","year":"1998","unstructured":"Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5(7):491\u2013502.","journal-title":"Acad Radiol"},{"issue":"11","key":"1688_CR29","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/00004424-199111000-00009","volume":"26","author":"G Schuhmann-Giampieri","year":"1991","unstructured":"Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol. 1991;26(11):975\u20139.","journal-title":"Invest Radiol"},{"issue":"6","key":"1688_CR30","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nrneph.2017.52","volume":"13","author":"C Zoccali","year":"2017","unstructured":"Zoccali C, Vanholder R, Massy ZA, et al. The systemic nature of CKD. Nat Rev Nephrol. 2017;13(6):344\u201358.","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"1688_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1053\/j.jrn.2023.09.001","volume":"34","author":"DH Kang","year":"2024","unstructured":"Kang DH, Streja E, You AS, et al. Hypoglycemia and Mortality Risk in Incident Hemodialysis Patients. J Ren Nutr. 2024;34(3):200\u20138.","journal-title":"J Ren Nutr"},{"issue":"1","key":"1688_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1053\/j.ackd.2019.01.004","volume":"26","author":"M Syed-Ahmed","year":"2019","unstructured":"Syed-Ahmed M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(1):8\u201315.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"7","key":"1688_CR33","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/RLI.0000000000000762","volume":"56","author":"KA Layne","year":"2021","unstructured":"Layne KA, Raja K, Dargan PI, Wood DM. Gadolinium concentrations in biological matrices from patients exposed to gadolinium-based contrast agents. Invest Radiol. 2021;56(7):458\u201364.","journal-title":"Invest Radiol"},{"issue":"7","key":"1688_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/RLI.0000000000000657","volume":"55","author":"KA Layne","year":"2020","unstructured":"Layne KA, Wood DM, Dixon-Zegeye M, et al. Establishing reference intervals for gadolinium concentrations in blood, plasma, and urine in individuals not previously exposed to gadolinium-based contrast agents. Invest Radiol. 2020;55(7):405\u201311.","journal-title":"Invest Radiol"},{"issue":"3","key":"1688_CR35","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1515\/cclm-2019-0607","volume":"58","author":"J Bornhorst","year":"2020","unstructured":"Bornhorst J, Wegwerth P, Day P, et al. Urinary reference intervals for gadolinium in individuals without recent exposure to gadolinium-based contrast agents. Clin Chem Lab Med. 2020;58(3):e87\u201390.","journal-title":"Clin Chem Lab Med"},{"key":"1688_CR36","unstructured":"Gadolinium, Serum Reference Values - Mayo Clinic Laboratories. Renal diagnostics catalog. https:\/\/renal.testcatalog.org\/show\/GDS."},{"key":"1688_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000001165","author":"JS McDonald","year":"2025","unstructured":"McDonald JS, Day PL, Spears GM, et al. Serum and urine gadolinium reference intervals in patients with normal renal function following gadobutrol administration. Invest Radiol. 2025. https:\/\/doi.org\/10.1097\/RLI.0000000000001165.","journal-title":"Invest Radiol"},{"issue":"8","key":"1688_CR38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/RLI.0000000000000045","volume":"49","author":"E Gheuens","year":"2014","unstructured":"Gheuens E, Daelemans R, Mesens S. Dialysability of gadoteric acid in patients with end-stage renal disease undergoing hemodialysis. Invest Radiol. 2014;49(8):505\u20138.","journal-title":"Invest Radiol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01688-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:19:57Z","timestamp":1790684397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01688-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,22]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1688"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01688-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,22]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by Jiangsu Hengrui Pharmaceuticals Co., Ltd.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Qiwen Han, Tengrui Yin and Yuanyuan Hang are employed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. Other authors all declare no conflicts of interest.","order":2,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the independent institutional ethics committees of all participating centers and was conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The datasets generated and analyzed during this study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all participants before trial enrollment.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors approved the manuscript for submission.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Han Qiwen and Rongjun Zhang contributed equally to this work. Han Qiwen led the scientific design, protocol development, data interpretation, and manuscript drafting. Rongjun Zhang coordinated the multicenter trial implementation and regulatory oversight. Tengrui Yin and Yuanyuan Huang provided scientific guidance and critically reviewed the manuscript. Zhao Wei served as the principal investigator at the lead site and oversaw participants enrollment and data collection. All other authors acted as principal investigators at their respective sites, responsible for local trial conduct and data acquisition. All authors reviewed and approved the final manuscript and are accountable for the work.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}